ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
Product Name: adb-fubinaca
CAS Number: 1445583-51-6
Molecular Formula: C21H23FN4O2
Molecular weight: 382.43
DeliveryTime: 3-5 days after received your deposit
PackAge: a foil bag
Production Capacity: 500 Kilogram/Week
Storage: Keep away from fire and heat source
LimitNum: 10 Gram
Some products exports to Europe, North America, Canada, Russia and other developed countries.
Products can be customized according to customer demand
my contact infomation is:
Email: firstname.lastname@example.org or email@example.com
Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body